Trials / Completed
CompletedNCT03689907
Early Chimerism Following Allogeneic Stem-Cell Transplant
Assessing the Predictive Potential of Early Chimerism Analysis Following Allogeneic Stem-Cell Transplant
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 40 (actual)
- Sponsor
- Dartmouth-Hitchcock Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Allogeneic stem cell transplant (allo-SCT) is a common treatment for variety of blood cancers. To determine how many cells are from the donor after transplant, doctors complete a "chimerism analysis" or a test of participant cells to look at the DNA. Chimerism testing helps doctors predict graft rejection or recurrence of disease. Doctors at NCCC do chimerism testing routinely and it is usually done between 30 and 100 days after transplantation. The researchers believe that analyzing chimerism sooner than 30 days after transplant may help identify problems earlier, get patients treatment sooner, and increase the chances of a successful transplant. The purpose of this study is to find out if doing chimerism testing earlier than the traditional approach is better for patient outcomes (about 14 days after transplantation rather than 30+ days). Information gained from this study can be used to help prevent some post-transplant complications such as graft loss, graft-versus-host disease, or even relapse for future patients. Also, the researchers hope to learn more about chimerism testing of cells of patients with haploidentical donors (donors who are only a "half-match" - such as a parent or child of the recipient), because there have not been many chimerism analysis studies done in this population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Chimerism Evaluation | Blood collection for chimerism evaluation will be performed on days +14/15-post transplant and +30-post transplant for each study participant. |
Timeline
- Start date
- 2019-12-19
- Primary completion
- 2024-11-30
- Completion
- 2024-12-30
- First posted
- 2018-10-01
- Last updated
- 2025-04-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03689907. Inclusion in this directory is not an endorsement.